维多珠单抗诱发的急性胰腺炎：首例报告临床病例。
Vedolizumab-induced acute pancreatitis: the first reported clinical case.
作者信息
Picardo Sherman, So Kenji, Venugopal Kannan, Chin Marcus
机构信息
Department of Gastroenterology, Royal Perth Hospital, Perth, Western Australia, Australia.
出版信息
BMJ Case Rep. 2018 Jan 5;2018:bcr-2017-222554. doi: 10.1136/bcr-2017-222554.
Abstract
Drug-induced acute pancreatitis (DIAP) is a rare, but clinically significant diagnosis. Vedolizumab, an αβ integrin inhibitor, which was approved in 2015 for treatment of moderate to severe inflammatory bowel disease, is a well-tolerated medication with a favourable safety profile and minimal serious adverse events in premarketing clinical trials. We present the first reported case of acute pancreatitis directly attributable to vedolizumab.
摘要
药物性急性胰腺炎（DIAP）是一种罕见但具有临床意义的诊断。维多珠单抗是一种αβ整合素抑制剂，于2015年被批准用于治疗中度至重度炎症性肠病，是一种耐受性良好的药物，在上市前临床试验中具有良好的安全性，严重不良事件极少。我们报告了首例直接归因于维多珠单抗的急性胰腺炎病例。
相似文献
1
Vedolizumab-induced acute pancreatitis: the first reported clinical case.维多珠单抗诱发的急性胰腺炎：首例报告临床病例。
BMJ Case Rep. 2018 Jan 5;2018:bcr-2017-222554. doi: 10.1136/bcr-2017-222554.
2
Acute Pancreatitis in a Patient With Ulcerative Colitis on Vedolizumab.
Inflamm Bowel Dis. 2020 Apr 11;26(5):e44. doi: 10.1093/ibd/izaa042.
3
Vedolizumab-Associated Pancreatitis in Paediatric Ulcerative Colitis: Functional Selectivity of the α4β7integrin and MAdCAM-1 Pathway?
J Crohns Colitis. 2018 Mar 28;12(4):507-508. doi: 10.1093/ecco-jcc/jjx167.
4
[Not Available].[无可用内容]
Ugeskr Laeger. 2024 May 27;186(22):V01240025. doi: 10.61409/V01240025.
5
The safety of vedolizumab for the treatment of ulcerative colitis.维多珠单抗治疗溃疡性结肠炎的安全性。
Expert Opin Drug Saf. 2017 Apr;16(4):501-507. doi: 10.1080/14740338.2017.1300251. Epub 2017 Mar 5.
6
The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data.维得利珠单抗在溃疡性结肠炎和克罗恩病中的安全性：全球上市后 4 年的数据。
J Crohns Colitis. 2020 Feb 10;14(2):192-204. doi: 10.1093/ecco-jcc/jjz137.
7
Acneiform eruption induced by vedolizumab.维多珠单抗诱发的痤疮样皮疹。
Dermatol Online J. 2018 Oct 15;24(10):13030/qt0vg996xr.
8
Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.维多珠单抗治疗溃疡性结肠炎的药效学评估。
Expert Opin Drug Metab Toxicol. 2016 Jul;12(7):833-42. doi: 10.1080/17425255.2016.1181171. Epub 2016 May 12.
9
Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.维多珠单抗治疗克罗恩病和溃疡性结肠炎的安全性。
Expert Opin Drug Saf. 2015;14(9):1473-9. doi: 10.1517/14740338.2015.1063612. Epub 2015 Jul 9.
10
The safety of vedolizumab for ulcerative colitis and Crohn's disease.维多珠单抗用于溃疡性结肠炎和克罗恩病的安全性。
Gut. 2017 May;66(5):839-851. doi: 10.1136/gutjnl-2015-311079. Epub 2016 Feb 18.
引用本文的文献
1
Predictors of Pancreatitis Among Patients with Inflammatory Bowel Disease Treated with Vedolizumab: Observation from a Large Global Safety Database.接受维多珠单抗治疗的炎症性肠病患者中胰腺炎的预测因素：来自大型全球安全数据库的观察结果
Drugs Real World Outcomes. 2023 Dec;10(4):557-564. doi: 10.1007/s40801-023-00386-y. Epub 2023 Sep 5.
2
Drug-Induced Acute Pancreatitis: An Evidence-Based Classification (Revised).药物性急性胰腺炎：一种基于证据的分类（修订版）。
Clin Transl Gastroenterol. 2023 Aug 1;14(8):e00621. doi: 10.14309/ctg.0000000000000621.
3
Doxycycline Induced Pancreatitis: An Uncommon Complication of a Common Drug.多西环素诱导的胰腺炎：一种常见药物的罕见并发症。
Pharmacy (Basel). 2022 Oct 30;10(6):144. doi: 10.3390/pharmacy10060144.
4
Systematic review-pancreatic involvement in inflammatory bowel disease.系统评价-炎症性肠病中的胰腺受累。
Aliment Pharmacol Ther. 2022 Jun;55(12):1478-1491. doi: 10.1111/apt.16949. Epub 2022 May 3.
5
Drug induced pancreatitis: A systematic review of case reports to determine potential drug associations.药物性胰腺炎：病例报告的系统回顾，以确定潜在的药物关联性。
PLoS One. 2020 Apr 17;15(4):e0231883. doi: 10.1371/journal.pone.0231883. eCollection 2020.
6
The Etiology of Pancreatic Manifestations in Patients with Inflammatory Bowel Disease.炎症性肠病患者胰腺表现的病因学
J Clin Med. 2019 Jun 26;8(7):916. doi: 10.3390/jcm8070916.
7
Pancreatic Involvement in Inflammatory Bowel Disease: A Review.炎症性肠病中的胰腺受累：综述
J Clin Med Res. 2018 Oct;10(10):743-751. doi: 10.14740/jocmr3561w. Epub 2018 Sep 10.
本文引用的文献
1
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium.维多珠单抗治疗中重度克罗恩病的真实世界有效性和安全性：来自美国VICTORY联盟的结果
Am J Gastroenterol. 2016 Aug;111(8):1147-55. doi: 10.1038/ajg.2016.236. Epub 2016 Jun 14.
2
Crohn's disease and acute pancreatitis. A review of literature.克罗恩病与急性胰腺炎。文献综述。
JOP. 2015 Mar 20;16(2):136-42. doi: 10.6092/1590-8577/2951.
3
Contemporary review of drug-induced pancreatitis: A different perspective.药物性胰腺炎的当代综述：一个不同的视角。
World J Gastrointest Pathophysiol. 2014 Nov 15;5(4):405-15. doi: 10.4291/wjgp.v5.i4.405.
4
Acute Pancreatitis Induced by Azathioprine and 6-mercaptopurine Proven by Single and Low Dose Challenge Testing in a Child with Crohn Disease.硫唑嘌呤和6-巯基嘌呤诱发急性胰腺炎，通过单剂量和低剂量激发试验在一名克罗恩病患儿中得到证实
Pediatr Gastroenterol Hepatol Nutr. 2012 Dec;15(4):272-5. doi: 10.5223/pghn.2012.15.4.272. Epub 2012 Dec 31.
5
Vedolizumab as induction and maintenance therapy for Crohn's disease.维得利珠单抗作为克罗恩病的诱导缓解和维持治疗药物。
N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739.
6
Vedolizumab as induction and maintenance therapy for ulcerative colitis.维得利珠单抗用于溃疡性结肠炎的诱导缓解和维持治疗。
N Engl J Med. 2013 Aug 22;369(8):699-710. doi: 10.1056/NEJMoa1215734.
7
Azathioprine or mercaptopurine-induced acute pancreatitis is not a disease-specific phenomenon.硫唑嘌呤或巯嘌呤引起的急性胰腺炎并非疾病特异性现象。
Aliment Pharmacol Ther. 2010 Jun;31(12):1322-9. doi: 10.1111/j.1365-2036.2010.04287.x. Epub 2010 Mar 6.
8
Drug-induced pancreatitis : incidence, management and prevention.药物性胰腺炎：发病率、管理与预防
Drug Saf. 2008;31(10):823-37. doi: 10.2165/00002018-200831100-00002.
9
Acute pancreatitis.急性胰腺炎
Lancet. 2008 Jan 12;371(9607):143-52. doi: 10.1016/S0140-6736(08)60107-5.
Zotero 插件